Beyond Air Inc
beyondair.netWhat Do They Do?
Sells nitric oxide generators and delivery systems to hospitals for newborn respiratory failure, and develops treatments for lung infections, solid tumors and neurological conditions.
10-K for FY2026, filed Jun 26, 2026We are a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (“NO”) generators and delivery…View ↗
LungFit® can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections via…View ↗
With Beyond Air’s focus on NO and its effect on the human condition, there are two additional programs that do not utilize our LungFit®…View ↗
The second program, which does not utilize the LungFit® platform, partially inhibits neuronal nitric oxide synthase (“nNOS”) in the brain…View ↗
How Do They Make Money?
Hospitals and medical facilities pay fixed monthly amounts to lease LungFit PH devices for terms of up to three years, with consumables included. Under distribution arrangements, customers buy devices and consumables and pay when the goods are delivered.
10-K for FY2026, filed Jun 26, 2026The Company generates revenue from the leases of its LungFit® PH devices to its customers under fixed fee arrangements over periods of up…View ↗
The Company elected the practical expedient applied to operating leases not to separate lease and non-lease components as long as the lease…View ↗
The Company also generates revenue from the sale of its LungFit® PH devices and consumables to its customers under distribution…View ↗
$7.7M
-
10-K for FY2026, filed Jun 26, 2026
$7.7M ↗
Who Are Their Customers?
The company markets directly to hospitals and medical facilities through its field sales team, and also sells devices and consumables through distribution arrangements.
10-K for FY2026, filed Jun 26, 2026The Company generates revenue from the leases of its LungFit® PH devices to its customers under fixed fee arrangements over periods of up…View ↗
The Company also generates revenue from the sale of its LungFit® PH devices and consumables to its customers under distribution…View ↗
We market directly to our customers through our field sales team. A separate team of clinical specialists provides the training necessary…View ↗
10-K for FY2026, filed Jun 26, 2026
For the year ended March 31, 2026, the Company derived 11% and 10% of its revenues from two customers. For the year ended March 31, 2025…View ↗
Do Revenues Turn Into Profits?
No. It lost $33.2M in FY2026.
10-K for FY2026, filed Jun 26, 2026
−$29MView ↗
10-K for FY2026, filed Jun 26, 2026
−$33.2MView ↗
10-K for FY2026, filed Jun 26, 2026
−$19.1MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q1 FY2027, filed Aug 13, 2026
−$7.9MView ↗
- ▲ +3% (Loss)
- vs −$7.7M in Q1 FY2026
-
Aug 18, 2026
Reaffirmed revenue guidance
Reaffirmed guidance of $8 million for calendar 2026 and $16-$18 million for calendar 2027.
Sources
8-K, filed Aug 18, 2026
The Company reaffirms its previously issued revenue guidance of $8 million for calendar year 2026, which does not include any revenue from…View ↗
Growing. Revenue grew 6.6x in 2 years, from $1.2M in FY2024 to $7.7M in FY2026, about 157% a year.
International distribution
The older report described a potential launch in Europe and globally; the latest describes regulatory approvals and distribution agreements with international partners, making partner-based international distribution part of the commercial plan.
10-K for FY2023, filed Jun 22, 2023 10-K for FY2026, filed Jun 26, 2026We also expect to be CE Mark certified under the EU Medical Device Regulation (“EU MDR”) in the EU in the second half of calendar year…View ↗
We initiated the first phase of our commercial launch in July 2022 (the limited launch phase to introduce Lungfit® PH and Beyond Air to…View ↗
Who Do They Compete With?
Competes with Mallinckrodt, Linde Group, Air Liquide, EKU, International Biomedical, Cahouet, ITC, VERO Biotech, Novan, SaNOtize, Third Pole, NovLead Biotechnology, and Shenzhen Respomed Medical Technology
10-K for FY2026, filed Jun 26, 2026The biotechnology, pharmaceutical and medical device industries are highly competitive. There are many pharmaceutical companies…View ↗
Loading...
